Skip to main content

Table 1 Description of the 24 subjects

From: Exercise induced hemoconcentration following spleen contraction in subjects with COPD

 

All (N = 24)

Hypoxic (N = 9)

Non-hypoxic (N = 15)

p-value

Male (N)

9

2

7

 

Age (years)

71 (8.8)

72 (8.2)

71 (9.0)

0.758

Height (cm)

166 (8.6)

161 (8.7)

168 (7.4)

0.034

Weight (kg)

69 (14.6)

75 (14.3)

66 (14.1)

0.145

BMI (kg/m2)

25 (5.5)

29 (5.7)

23 (4.1)

0.008

FEV1(Liters)

0.85 (0.32)

0.94 (0.31)

0.8 (0.32)

0.308

FEV1 (% of predicted)

33 (11.7)

39 (12.2)

30 (10.3))

0.053

FVC (Liters)

1.7 (0.5)

1.9 (0.6)

1.7 (0.4)

0.481

FVC (% of predicted)

52 (14.8)

60 (17.6)

47 (10.4)

0.026

FEV1/FVC

0.49 (0.1)

0.52 (0.1)

0.47 (0.1)

0.290

PaO2 (kPa)

8.8 (1.5)

7.4 (0.8)

9.5 (1.2)

0.001

PaCO2(kPa)

5.4 (0.6)

5.6 (0.5)

5.2 (0.6)

0.034

6-min walking test (meters)

297 (95)

267 (87)

314 (98)

0.237

LTOT (N)

4

3

1

 

LAMA (N)

14

6

8

 

ICS (N)

19

7

12

 

SAMA (N)

6

4

2

 

SABA (N)

9

3

6

 

Hypertension (N)

7

4

3

 

Coronary heart disease (N)

6

3

3

 

Diabetes (N)

4

2

2

 

Claudicatio intermittens (N)

2

1

1

 

Current smoker (N)

2

2

  

Former smoker (N)

22

7

15

 
  1. Table text: Data presented as mean (SD). Lung function volumes are post-bronchodilation values. BMI body mass index, FEV forced expiratory volume, FVC forced vital capacity, PaO 2 partial pressure of arterial oxygen, PaO 2 partial pressure of arterial carbon dioxide, LTOT long-term oxygen therapy, LAMA long-acting muscarinic antagonist, ICS inhaled corticosteroid, LABA long-acting beta2-agonist, SAMA short-acting muscarinic antagonist, SABA short-acting beta2-agonist, N number of subjects